In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

France’s main free-to-air broadcasters France Télévisions, M6 and TF1 have joined forces with the country’s film and TV ...

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...

Jacobs acknowledged that Novavax does not have the market leverage and scale of French drugmaker Sanofi, with which it signed ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

France's biggest-selling medication. Freshfields is advising Sanofi on corporate and consumer healthcare aspects of the deal, which is valued at around €16 billion ($17.28 billion). Sanofi would ...

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and fast-moving consumer healthcare company. Bpifrance is expected to participate as a minority shareholder with ...

Paris “must block the sale” using powers to protect strategic sectors, said Manuel Bompard, a senior lawmaker in hard-left France Unbowed (LFI), in an interview with broadcaster TF1. Politicians and ...